Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.
The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group, and Oriza Holdings.
Accro Bioscience plans to use the proceeds from the financing to fund the Phase IIb clinical trial of AC-101, an RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for inflammatory and autoimmune diseases.
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
Accro Bioscience completes USD50m Series C financing
Atisama Therapeutics reports progress in Phase 1 study of RB042
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
Trellus Health renews licensing agreement with Pfizer
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
GSK secures China approval for Exdensur to treat nasal polyp condition
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints